Allarity Therapeutics Delays 10-Q Filing

Allarity Therapeutics ( (ALLR) ) has released a notification of late filing.

Allarity Therapeutics, Inc. has filed a Form 12b-25, indicating a delay in submitting its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for this delay is the ongoing review of the company’s financial statements by its certifying auditors, which has not yet been completed. The company expects to file the delayed report within the five-day extension period allowed. There are no anticipated significant changes in the financial results compared to the same period last year. Allarity Therapeutics is actively working to ensure compliance, with the notification signed by Jeff Ervin, the Chief Financial Officer.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Average Trading Volume: 471,886

Technical Sentiment Signal: Sell

Current Market Cap: $14.47M

Find detailed analytics on ALLR stock on TipRanks’ Stock Analysis page.